Evaluation of HER2 protein overexpression in non-muscle invasive bladder cancer with emphasis on tumour grade and recurrence;Evaluación de la sobreexpresión de proteína HER2 en cáncer vesical no músculo invasivo con énfasis en el grado tumoral y en la recurrencia

Actas Urologicas Espanolas

Volumn 35, Issue 4, 2011, Pages 189-194

  Janane, A ^a   Hajji, F ^a   Ismail, T O ^a   Elondo, J C ^a   Ghadouane, M ^a   Ameur, A ^a   Abbar, M ^a   Bouzidi, A ^a  

^a MILITARY HOSPITAL MOHAMMED V   (Morocco)

Author keywords

Bladder TCC; HER2 protein; Prognosis marker; Tumour behaviour

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; TUMOR PROTEIN;

AGED; ARTICLE; BIOSYNTHESIS; BLADDER TUMOR; CANCER INVASION; CANCER STAGING; CHEMISTRY; CYSTECTOMY; CYSTOSCOPY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN MICROARRAY; SINGLE BLIND PROCEDURE; TRANSITIONAL CELL CARCINOMA; VASCULARIZATION;

AGED; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; CYSTOSCOPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN ARRAY ANALYSIS; RECEPTOR, ERBB-2; SINGLE-BLIND METHOD; URINARY BLADDER NEOPLASMS;

EID: 79953328483     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2010.11.017     Document Type: Article

References (20)

1. Elisa S, Ali HS, Al tonsi AH, Zaglol A, El ahmady O. HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Clin Biochemistry. 2005;38:142-8.
2. Christopher L, Coogan A, Estrada CR, Kapur S, Kenneth JB. HER2/neu protein overexpression and gene amplification in transitional cell carcinoma of the bladder. Urology. 2004;63:786-90. (Pubitemid 38479440)
3. Raica M, Zylis D, Cinpeam AM. Cytokeratin 20, 34 beta E12 and overexpression of HER-2/neu in urine cytology as predictors of recurrences in superficial urothelial carcinoma. J Morphol Embryo. 2005;46:11-5.
4. Wallerand H, Bernhard JC, Culine S, Ballanger P, Robert G, Reiter RE, et al. Targeted therapies in non muscle invasive bladder cancer according to the signal pathways. Urologic Oncology. 2009;13:624-32.
5. Latif Z, Watters D, Dunn I, Grigor M, Underwood M, Bartlett JM. HER2/neu gene amplification and protein overexpression in GIII PT2 transitional carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer. 2004;40:56-63. (Pubitemid 37542318)
6. Babjuk M, Oosterlink W, Sylvester R, Kaasien E, Böhle A, Palo-Redorta J. Guía clínica del carcinoma urotelial no músculo invasivo de la Asociación Europea de Urología. Actas Urol Esp. 2009;33:361-71.
7. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urologic Pathology Classification of urothelial (transitional) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22: 1435-48.
8. Gelabert A. Monografías de Urología Oncológica. Cáncer vesical que no infiltra músculo. Recomendaciones diagnósticas, terapéuticas y de seguimiento. Barcelona: Marge Medical Books; 2007.
9. Langner C, Gross C, Peter R, Ratschek M, Rucshoff J, Zigeuner R. HER2 protein over expression and amplification in transitional cell carcinoma: systemic analysis applying tissue microarray technique. Urology. 2005;65:176-80. (Pubitemid 40169640)
10. Press MF, Hung G, Godolphin, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue: potential source of error in Immunohistochemical studies of oncognene expression. Cancer Res. 1994;54:2771-7. (Pubitemid 24173773)
11. Pérez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescent in situ hybridization. Mayo Clin Proc. 2002;77:148-54.
12. Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T, et al. HER overexpression in muscle invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer. 2002;102:514-8. (Pubitemid 35316007)
13. Wester K, Sjostrom A, De la Toore M, Carlson J, Malmstrum PU. HER-2 a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol. 2002;41:282-8.
14. Sauter G, Moch H, Moore D. Heterogenicity of HER2 gene amplification in bladder cancer? Cancer Res. 1993;53:2199-203.
15. Underwood M, Bartlett J, Reeves J, Cooke TC. HER-2 gene amplification: a molecular marker in recurrent bladder cancer? Cancer Res. 1995;55:2422-30.
16. Latif Z, Watters AD, Dunn I, Underwood MA, Grigor KM, Bartlett JMS. HER/neu overexpression in the development of muscle invasive TCC of the bladder. Br J Cancer. 2003;89:1305-9. (Pubitemid 37363421)
17. Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, et al. HER2 and TOP 2A coamplification in urinary bladder cancer. Int J Cancer. 2003;107:764-72. (Pubitemid 37339730)
18. Eltze E, Wulfing C, Von Struensee D, Hansjurgen P, Horst B, Lothar H. Cox2 and HER2/neu coexpression in invasive bladder cancer. Int J Oncol. 2005;26:1525-31.
19. Tetu B, Fradet Y, Allard P, Veilleux C, Rberge N, Bernard P. Prevalence and clinical significance of the HER-2/neu, p53 and Rb expression in primary superficial bladder cancer. J Urol. 1996;155:1784-8. (Pubitemid 26127001)
20. Lebret T, Méjean A. Metastatic Transitional cell carcinomas: the future and perspectives. Prog Urol. 2008;7:277-84.